NON-SMALL CELL LUNG CANCER

This study tests a new drug, iruplinalkib, in 20 adults with advanced ALK-positive lung cancer that got worse or caused side effects after treatment with lorlatinib. Researchers will track how long the drug controls the cancer and monitor safety in real-world settings. The goal i…

This study tests whether adding new drugs to standard immunotherapy (pembrolizumab) can better control advanced non-small cell lung cancer. About 90 people with untreated stage IV lung cancer will receive these combinations. The goal is to see if tumors shrink and to check for si…

This study tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein. Participants must have already tried at least one other cancer treatment. The goal is to see if the drug can shrink tumors or stop them from growing. This is not…

This study tests a new drug, firmonertinib, against two standard treatments for people with advanced non-small-cell lung cancer that has specific rare genetic changes (EGFR PACC mutations). About 480 participants who have not had prior treatment for advanced disease will be rando…

This study tests whether adding the experimental drug SKB264 to the standard targeted therapy osimertinib works better than osimertinib alone for people with a specific type of advanced lung cancer (EGFR-mutated non-squamous non-small cell lung cancer). About 420 adults who have …

This study tests a new daily pill, VS-7375, for people with advanced cancers (like pancreatic, lung, or colorectal) that have a specific KRAS G12D mutation. The trial will check if the drug is safe and shrinks tumors when used alone or with other treatments. About 295 adults will…

This study is testing whether a short course of low-dose radiation followed by immunotherapy and chemotherapy can shrink tumors before surgery in people with stage II to III non-small cell lung cancer. The goal is to see if this approach makes surgery more effective and reduces t…

This early-stage study tests a new cancer treatment called FT836, which uses donor immune cells specially designed to attack tumors. It is for people with advanced lung, colorectal, breast, ovarian, endometrial, or head and neck cancers that have not responded to standard treatme…

This study compares two treatments for early-stage non-small cell lung cancer in patients who are high-risk for surgery. One group gets a precise, high-dose radiation treatment (SAbR), while the other has surgery to remove the tumor. The goal is to see which approach helps patien…

This study tests a new treatment called OBX-115 for people with advanced melanoma or non-small cell lung cancer that has spread or come back. OBX-115 uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are modified in the lab to include a protein (IL15) that h…

This study tests an experimental drug called VMD-928, taken as a pill, alone or with pembrolizumab (an immunotherapy) in adults with advanced solid tumors or lymphoma that have stopped responding to standard treatments. The goal is to find safe doses and see if the drug shrinks t…

This early-phase study tests a new drug called BBO-11818 in adults with advanced lung, pancreatic, or colorectal cancers that have a KRAS mutation. The main goals are to check safety and find the best dose, while also seeing if the drug can shrink tumors. About 387 participants w…

This study tests a new oral drug, STX-721, in people with advanced non-small cell lung cancer that has specific genetic changes (EGFR or HER2 exon 20 insertions). The goal is to find a safe dose and see if it can shrink tumors. About 251 participants will take the pill daily, and…

This study tests a new drug, LY4052031, in people with advanced or spreading solid tumors, including bladder, breast, and lung cancers. The drug is designed to attach to a protein on cancer cells and deliver a toxic payload to kill them. The trial has two parts: first to find the…

This study is for people with early-stage non-small cell lung cancer who have finished standard treatment. A blood test looks for tiny bits of cancer DNA (ctDNA) that might mean the cancer could come back. If the test is positive, participants get a drug called durvalumab to try …

This study looks at whether giving radiation therapy after surgery and chemo-immunotherapy can help people with stage III non-small cell lung cancer who still have cancer cells remaining after treatment. About 118 adults will be randomly assigned to receive either radiation or no…

This early-phase study tests a new oral drug, BGB-43395, that blocks a protein called CDK4 to slow cancer growth. It is for people with advanced hormone-positive, HER2-negative breast cancer or other solid tumors that have spread. The main goal is to find the safest and most effe…

This study tests an experimental oral drug, S241656, in adults with advanced cancers that have certain gene changes (like KRAS or BRAF mutations). The drug is given alone or with other cancer treatments. The goal is to find safe doses and see if the drug can shrink tumors. About …

This study is for people with non-small cell lung cancer that has spread to the brain (1 to 10 spots). Researchers want to see if using MRI-guided radiation without the usual extra safety margins can still be effective while lowering the risk of brain tissue damage. About 168 adu…

This study tests a drug called lazertinib, given alone or with chemotherapy, before surgery for people with a specific type of lung cancer (EGFR-mutated non-small cell lung cancer). The goal is to see if the drug can shrink tumors enough to improve surgery results. About 160 adul…

This study tests a drug called zanidatamab in people with certain advanced cancers (lung, sarcoma, head & neck, colorectal, or endometrial) that have a specific change in the HER2 gene. The goal is to see if the drug can shrink tumors. About 105 adults will receive the drug every…

This study tests whether adding valemetostat to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with advanced non-small cell lung cancer that has high PD-L1 levels (50% or more) and no targetable gene changes. About 137 adults who have no…

This study tests the safety of combining two drugs, lorlatinib and ramucirumab, for people with advanced ALK-rearranged non-small cell lung cancer. Researchers will find the best dose that causes few side effects, then check if it helps control the cancer. About 56 adults with me…

This phase 3 study tests whether adding the diabetes drug metformin to standard targeted therapy (tyrosine kinase inhibitors) can help control advanced non-small cell lung cancer with EGFR mutations. About 312 adults with stage IIIB or IV lung cancer will receive either metformin…

This early-phase study tests a new drug called DR-0202 in about 96 people with advanced solid tumors (like breast, lung, or pancreatic cancer) that have not responded to at least two prior treatments. The main goal is to check the drug's safety and find the right dose. Participan…

This study tests a drug called pyrotinib as a first treatment for people with advanced non-small cell lung cancer that has a specific change in the HER2 gene. The drug works by blocking signals that help cancer cells grow. The trial will check if the drug shrinks tumors and how s…

This study is testing whether a lower dose of the targeted cancer drug osimertinib can safely control advanced EGFR-positive non-small cell lung cancer. About 58 adults whose cancer has not responded to surgery or radiation will take 80 mg every other day. Researchers will monito…

This study tests a new drug called SHR-A2102 combined with other cancer treatments for people with a type of lung cancer that can be removed with surgery. The goal is to see if the combination helps shrink or eliminate the cancer before surgery and prevents it from coming back af…

This study tests whether combining a targeted drug (adagrasib) with precise radiation (SRS) can better control brain tumors in people with a specific type of lung cancer (KRAS G12C mutation). About 30 adults with untreated brain metastases will receive both treatments. The goal i…

This study tests whether combining an immunotherapy drug (atezolizumab), an immune booster (BDB001), and targeted radiation can help control advanced solid tumors. About 247 adults with cancers like pancreatic, lung, or breast cancer will receive the treatment. The goal is to see…

This study tests two experimental drugs, BNT326 and BNT327, together in people with advanced non-small cell lung cancer that has spread or come back. The goal is to find the best dose and see if the combination can shrink tumors. About 420 adults will take part, including those w…

This study tests a new drug called dositinib for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation). The goal is to find the safest dose and see if it can shrink tumors. About 153 adults aged 18-75 who have already tried other treat…

This study tests whether removing extra safety margins during precise, adaptive radiation therapy can lower the risk of lung side effects while still controlling tumors. It involves 130 adults with early-stage non-small cell lung cancer or a few lung tumors that have spread from …

This study tests an experimental drug called telisotuzumab vedotin in adults with a specific type of advanced lung cancer (non-small cell lung cancer that has a high level of a protein called c-Met). About 150 participants worldwide will receive one of three different doses of th…

This study looks at whether adding a precise type of radiation (stereotactic radiosurgery) to standard drug treatments can better control brain metastases in people with melanoma or non-small cell lung cancer. About 180 participants with newly diagnosed, untreated brain metastase…

This study tests whether adding BIO 300 to standard chest radiation can prevent severe lung inflammation (pneumonitis) in people with early-stage non-small cell lung cancer who also have interstitial lung disease (lung scarring). About 25 adults will receive the combination and b…

This study tests whether adding targeted radiotherapy to usual drug treatments can slow the growth or spread of lung cancer in people with metastatic non-small-cell lung cancer. About 320 participants whose cancer has started to grow in a limited number of spots while on first-li…

This study tests an experimental drug called CP-383 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to find the safest dose and see if the drug can shrink or slow cancer growth. About 150 participants will take CP-383 daily …

This study tests a daily pill called zongertinib for people with early-stage non-small cell lung cancer that has a specific HER2 gene change. After surgery to remove the cancer, participants either take zongertinib for up to 3 years or receive standard care (immunotherapy or obse…

This study tests whether the immunotherapy drug cemiplimab can help prevent lung cancer from coming back after surgery. About 390 adults with stage II-IIIA non-small cell lung cancer who have not had chemotherapy will receive either cemiplimab or no additional treatment. The goal…

This study tests whether a combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy works better than the current standard (pembrolizumab plus chemotherapy) for people with advanced non-squamous lung cancer whose tumors have PD-L1 levels of 1% or higher…

This early-phase study tests a new drug called 177Lu-RAD204 in people with advanced solid tumors (like lung, breast, or skin cancer) that have not responded to other treatments. The drug delivers a small amount of radiation directly to cancer cells by targeting a protein called P…

This study tests whether a new drug called ivonescimab, when combined with chemotherapy, works better than the current standard treatment (pembrolizumab plus chemotherapy) for people with advanced non-small cell lung cancer that has spread. About 1,600 adults with stage IV lung c…

This study tests whether adding high-dose radiation to standard drug therapy (chemotherapy or immunotherapy) improves survival in people with non-small cell lung cancer that has spread to up to 5 spots. About 240 participants will be randomly assigned to receive either standard t…

This early-phase study tests a new drug called GNC-077 in about 20 adults with advanced non-small cell lung cancer or other solid tumors that have spread. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive the …

This study tests whether a new drug called rilvegostomig, when added to standard chemotherapy, helps people with advanced squamous non-small cell lung cancer live longer or delay cancer growth. It is for people whose tumors have a specific protein (PD-L1). About 880 participants …

This study tests an experimental drug called GV20-0251 in adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug can shrink or control the cancer. About 350 participants with various cancer types will take part in thi…

This study is testing two different dosing schedules for a new, injectable form of an immunotherapy drug (nivolumab) when given with another immunotherapy (ipilimumab) and standard chemotherapy. It aims to see how the body processes the drugs and how safe they are for people with…

This study tests an experimental drug called TQB2102 for people with advanced non-small cell lung cancer that has a HER2 gene abnormality. The drug is designed to deliver a strong cancer-killing agent directly to tumor cells while sparing healthy tissue. About 270 adults aged 18-…

This study tests two drugs, GEN-725 and dositinib, together in people with advanced lung cancer that has a specific gene change (EGFR mutation). The goal is to see if the combination is safe and can shrink tumors or slow the cancer's growth. About 110 adults aged 18-75 are taking…

This study tests an experimental drug that delivers radiation directly to cancer cells by targeting a protein called Nectin-4. It is for people with advanced solid tumors (like bladder, breast, lung, or cervical cancer) that have not responded to prior treatments. The goal is to …

This early-phase study tests a new treatment for people with advanced lung cancer that has not responded to standard therapies. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells. The main goal is to find out if the trea…

This program provides early access to the investigational drug zidesamtinib for people with advanced ROS1-positive non-small cell lung cancer or other solid tumors who have run out of standard options and cannot join a clinical trial. Participants must have tried at least one pri…

This study tests whether adding nitroglycerin patches to standard radiation therapy improves outcomes for people with advanced lung cancer (with a specific EGFR gene change) that has spread to the brain. About 74 participants will receive either radiation alone or radiation plus …

This phase 3 trial tests whether a new drug called RC148, combined with chemotherapy, works better than the standard immunotherapy tislelizumab plus chemotherapy for people with advanced squamous non-small cell lung cancer who haven't had treatment before. About 574 adults aged 1…

This study tests an experimental oral drug called 7HP349 (Alintegimod) combined with standard immunotherapy drugs (ipilimumab and nivolumab) in adults with advanced solid tumors like melanoma, lung, kidney, or liver cancer that have not responded to prior treatments. The goal is …

This study tests whether adding a third drug to standard immunotherapy (cemiplimab) plus chemotherapy helps shrink early-stage non-small cell lung cancer more before surgery. About 120 adults with stage II-IIIB lung cancer that can be removed will be randomly assigned to one of t…

This early-phase study is testing a new radioactive imaging agent called [18F]-αvβ6-BP to see if it can better detect and monitor non-small cell lung cancer that has spread to the brain. About 20 adults with this type of lung cancer and brain metastases will receive a PET/CT scan…

This study is testing a new type of PET scan that uses a special probe called 68Ga-TOI-1 to find and stage lung cancer. The probe targets a protein (CDH3) found only on cancer cells, which may make the scan more precise than current methods. About 80 adults with suspected or conf…

This study looks at whether a gentle exercise program is practical and helpful for people with lung cancer who are getting radiation therapy, along with their family caregivers. About 40 pairs (patient plus caregiver) will take part. The goal is to see if the program improves qua…

This study enrolls 318 Black patients with advanced non-small cell lung cancer to see how well the immunotherapy drug pembrolizumab (with or without chemotherapy) works in real-world settings. Researchers will track survival and tumor progression, and look for biomarkers in the b…

This study will collect tumor and blood samples from 1100 people with various cancers (like head and neck, ovarian, and lung cancer) to measure how active certain immune cells are. The goal is to learn more about the body's natural immune response to cancer, not to test a new tre…

This study is not testing a new drug. Instead, it follows about 130 people with advanced EGFR-mutant non-small cell lung cancer who are starting standard treatment with osimertinib. Researchers will collect detailed information on how long the treatment controls the cancer and ho…

This study tests whether a natural compound called urolithin A can improve the immune response in people with solid tumors (like lung cancer or melanoma) who are starting immunotherapy. About 45 participants will receive either urolithin A or a placebo alongside their standard ca…

This study looks at whether a lab-grown model made from a patient's own lung cancer cells can help doctors choose the most effective drugs. Researchers will compare the model's predictions to how the patient actually responds to treatment. About 250 adults with non-small cell lun…

This study is testing whether a simple rectal mucus sample can detect DNA changes linked to lung, pancreatic, bladder, and colorectal cancers. Researchers will collect samples from 450 adults using a special device and analyze them for genetic and epigenetic markers. The goal is …

This study looks at 75 adults with non-small cell lung cancer who are receiving pembrolizumab (Keytruda). Researchers want to see if the amount of drug in a patient's blood is linked to how well the cancer shrinks or if side effects occur. By monitoring drug levels over time, the…

This study uses surveys to find out what factors are most important to Chinese patients and doctors when choosing the first targeted therapy for advanced non-small cell lung cancer. About 590 participants (patients and physicians) will share their preferences through a special qu…

This study is testing whether an artificial intelligence (AI) tool can help connect cancer patients with the right clinical trials. Researchers will enroll up to 50,000 people with various cancers and use the AI to suggest trials based on their tumor's genetic markers. The goal i…